{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:42:52Z","timestamp":1791218572699,"version":"4.1.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"24","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tumor necrosis factor\u2013related apoptosis-inducing ligand (TRAIL) and its agonistic antibodies, which are currently in early clinical trials for treating various malignancies, induce apoptosis through triggering of either TRAIL-R1 or TRAIL-R2. Based on studies using agonistic monoclonal antibodies, we recently proposed that primary chronic lymphocytic leukemic cells seem to signal apoptosis primarily through TRAIL-R1. We have now synthesized mutant forms of TRAIL specific for TRAIL-R1 or TRAIL-R2. The selectivity of these mutants to induce apoptosis in cell lines is due to selective binding to their cognate receptors resulting in apoptosis via formation of a death-inducing signaling complex. Using these mutants, we now unequivocally show that primary cells from patients with chronic lymphocytic leukemia and mantle cell lymphoma signal to apoptosis almost exclusively through TRAIL-R1. Thus, no significant therapeutic benefit can be anticipated from treating such patients with agents currently in clinical trials that signal predominantly through TRAIL-R2, such as HGS-ETR2 or Apo2L\/TRAIL. Our study highlights the necessity to determine whether primary cells from a particular tumor signal via TRAIL-R1 or TRAIL-R2. Such information will provide a rational approach to optimize TRAIL therapy. (Cancer Res 2005; 65(24): 11265-70)<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-2801","type":"journal-article","created":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T17:57:39Z","timestamp":1134669459000},"page":"11265-11270","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies"],"prefix":"10.1158","volume":"65","author":[{"given":"Marion","family":"MacFarlane","sequence":"first","affiliation":[{"name":"1Medical Research Council, Toxicology Unit, Hodgkin Building, University of Leicester, Leicester and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Kohlhaas","sequence":"additional","affiliation":[{"name":"1Medical Research Council, Toxicology Unit, Hodgkin Building, University of Leicester, Leicester and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"2Manchester Interdisciplinary Biocentre, School of Chemical Engineering and Analytical Science, University of Manchester, The Mill, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"1Medical Research Council, Toxicology Unit, Hodgkin Building, University of Leicester, Leicester and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"1Medical Research Council, Toxicology Unit, Hodgkin Building, University of Leicester, Leicester and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2005,12,15]]},"reference":[{"key":"2022061621072182100_B1","doi-asserted-by":"crossref","unstructured":"Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol\u20082000;2:241\u20133.","DOI":"10.1038\/35008667"},{"key":"2022061621072182100_B2","doi-asserted-by":"crossref","unstructured":"Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas\/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J\u20081995;14:5579\u201388.","DOI":"10.1002\/j.1460-2075.1995.tb00245.x"},{"key":"2022061621072182100_B3","doi-asserted-by":"crossref","unstructured":"Sprick MR, Weigand MA, Rieser E, et al. FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity\u20082000;12:599\u2013609.","DOI":"10.1016\/S1074-7613(00)80211-3"},{"key":"2022061621072182100_B4","doi-asserted-by":"crossref","unstructured":"Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer\u20082002;2:420\u201330.","DOI":"10.1038\/nrc821"},{"key":"2022061621072182100_B5","doi-asserted-by":"crossref","unstructured":"Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer\u20082005;92:1430\u201341.","DOI":"10.1038\/sj.bjc.6602487"},{"key":"2022061621072182100_B6","doi-asserted-by":"crossref","unstructured":"Snell V, Clodi K, Zhao S, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol\u20081997;99:618\u201324.","DOI":"10.1046\/j.1365-2141.1997.4393250.x"},{"key":"2022061621072182100_B7","doi-asserted-by":"crossref","unstructured":"MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene\u20082002;21:6809\u201318.","DOI":"10.1038\/sj.onc.1205853"},{"key":"2022061621072182100_B8","doi-asserted-by":"crossref","unstructured":"Almasan A, Ashkenazi A. Apo2L\/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev\u20082003;14:337\u201348.","DOI":"10.1016\/S1359-6101(03)00029-7"},{"key":"2022061621072182100_B9","doi-asserted-by":"crossref","unstructured":"Inoue S, MacFarlane M, Harper N, et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ\u20082004;11Suppl 2:S193\u2013206.","DOI":"10.1038\/sj.cdd.4401535"},{"key":"2022061621072182100_B10","doi-asserted-by":"crossref","unstructured":"MacFarlane M, Inoue S, Kohlhaas SL, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ\u20082005;12:773\u201382.","DOI":"10.1038\/sj.cdd.4401649"},{"key":"2022061621072182100_B11","doi-asserted-by":"crossref","unstructured":"Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med\u20082001;7:954\u201360.","DOI":"10.1038\/91000"},{"key":"2022061621072182100_B12","doi-asserted-by":"crossref","unstructured":"Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of Apoptosis-inducing ligand 2L\/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem\u20082005;280:2205\u201312.","DOI":"10.1074\/jbc.M410660200"},{"key":"2022061621072182100_B13","doi-asserted-by":"crossref","unstructured":"MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem\u20081997;272:25417\u201320.","DOI":"10.1074\/jbc.272.41.25417"},{"key":"2022061621072182100_B14","doi-asserted-by":"crossref","unstructured":"Hymowitz SG, Christinger HW, Fuh G, et al. Triggering cell death: the crystal structure of Apo2L\/TRAIL in a complex with death receptor 5. Mol Cell\u20081999;4:563\u201371.","DOI":"10.1016\/S1097-2765(00)80207-5"},{"key":"2022061621072182100_B15","doi-asserted-by":"crossref","unstructured":"Mongkolsapaya J, Grimes JM, Chen N, et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol\u20081999;6:1048\u201353.","DOI":"10.2210\/pdb1d4v\/pdb"},{"key":"2022061621072182100_B16","doi-asserted-by":"crossref","unstructured":"Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol\u20081993;234:779\u2013815.","DOI":"10.1006\/jmbi.1993.1626"},{"key":"2022061621072182100_B17","doi-asserted-by":"crossref","unstructured":"Peter ME, Krammer PH. The CD95(APO-1\/Fas) DISC and beyond. Cell Death Differ\u20082003;10:26\u201335.","DOI":"10.1038\/sj.cdd.4401186"},{"key":"2022061621072182100_B18","doi-asserted-by":"crossref","unstructured":"Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol\u20082004;124:130\u201340.","DOI":"10.1046\/j.1365-2141.2003.04761.x"},{"key":"2022061621072182100_B19","doi-asserted-by":"crossref","unstructured":"Gouet P, Courcelle E, Stuart DI, Metoz F. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics\u20081999;15:305\u20138.","DOI":"10.1093\/bioinformatics\/15.4.305"},{"key":"2022061621072182100_B20","unstructured":"DeLano W. The PyMOL molecular graphics system http:\/\/www.pymol.org 2002."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/24\/11265\/2538378\/11265-11270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/24\/11265\/2538378\/11265-11270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:57:06Z","timestamp":1655420226000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/24\/11265\/518752\/TRAIL-Receptor-Selective-Mutants-Signal-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,15]]},"references-count":20,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2005,12,15]]},"published-print":{"date-parts":[[2005,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-2801","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,15]]}}}